Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.

Ogi S, Fujita H, Kashihara M, Yamamoto C, Sonoda K, Okamoto I, Nakagawa K, Ohdo S, Tanaka Y, Kuwano M, Ono M.

Cancer Sci. 2013 May;104(5):573-83. doi: 10.1111/cas.12117. Epub 2013 Mar 8.

PMID:
23360489
[PubMed - indexed for MEDLINE]
2.

A role for sorting nexin 2 in epidermal growth factor receptor down-regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein trafficking.

Gullapalli A, Garrett TA, Paing MM, Griffin CT, Yang Y, Trejo J.

Mol Biol Cell. 2004 May;15(5):2143-55. Epub 2004 Feb 20.

PMID:
14978220
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.

Mol Cancer Res. 2009 Oct;7(10):1736-43. doi: 10.1158/1541-7786.MCR-08-0504. Epub 2009 Oct 6.

PMID:
19808904
[PubMed - indexed for MEDLINE]
Free Article
4.

Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.

Nishimura Y, Takiguchi S, Ito S, Itoh K.

Int J Oncol. 2014 Feb;44(2):412-26. doi: 10.3892/ijo.2013.2194. Epub 2013 Nov 28.

PMID:
24297483
[PubMed - indexed for MEDLINE]
5.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. Epub 2007 Dec 18.

PMID:
18093943
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M, Puri N.

PLoS One. 2013 Nov 4;8(11):e78398. doi: 10.1371/journal.pone.0078398. eCollection 2013.

PMID:
24223799
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

PMID:
22844075
[PubMed - indexed for MEDLINE]
Free Article
8.

Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.

Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Clin Cancer Res. 2009 Feb 1;15(3):907-13. doi: 10.1158/1078-0432.CCR-08-2251.

PMID:
19188161
[PubMed - indexed for MEDLINE]
Free Article
9.

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.

La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR.

PLoS One. 2013 Oct 22;8(10):e78656. doi: 10.1371/journal.pone.0078656. eCollection 2013.

PMID:
24167634
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.

Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.

BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.

PMID:
22436374
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.

Nishimura Y, Takiguchi S, Yoshioka K, Nakabeppu Y, Itoh K.

Int J Oncol. 2012 Oct;41(4):1520-30. doi: 10.3892/ijo.2012.1578. Epub 2012 Jul 31.

PMID:
22859339
[PubMed - indexed for MEDLINE]
12.

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.

Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T.

Clin Cancer Res. 2010 Nov 15;16(22):5489-98. doi: 10.1158/1078-0432.CCR-10-1371. Epub 2010 Nov 9.

PMID:
21062933
[PubMed - indexed for MEDLINE]
Free Article
13.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Cancer Sci. 2010 Jan;101(1):167-72. doi: 10.1111/j.1349-7006.2009.01368.x. Epub 2009 Sep 14.

PMID:
19804422
[PubMed - indexed for MEDLINE]
14.

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC.

Br J Cancer. 2008 Sep 16;99(6):911-22. doi: 10.1038/sj.bjc.6604559.

PMID:
19238632
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
[PubMed - indexed for MEDLINE]
16.
17.

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.

Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.

PMID:
20647329
[PubMed - indexed for MEDLINE]
Free Article
18.

The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.

Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, Williams BJ, Cardelli JA.

Clin Cancer Res. 2009 Aug 1;15(15):4885-94. doi: 10.1158/1078-0432.CCR-09-0109. Epub 2009 Jul 28.

PMID:
19638461
[PubMed - indexed for MEDLINE]
Free Article
19.

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.

Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, Zhou CC.

Asian Pac J Cancer Prev. 2012;13(1):255-60.

PMID:
22502680
[PubMed - indexed for MEDLINE]
Free Article
20.

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S.

Cancer Res. 2008 Nov 15;68(22):9479-87. doi: 10.1158/0008-5472.CAN-08-1643.

PMID:
19010923
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk